Azaindole derivatives as rho- kinase inhibitors
AssigneeChiesi Farmaceutici S.p.A.
InventorsAlessandro ACCETTA, Fabio RANCATI, Christine EDWARDS, Andrea NUZZI
Life of this patent
Estimating the term…
Abstract
The invention relates to compounds of formula I inhibiting Rho Kinase that are tyrosine analogues derivatives, processes of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
Claims21
A compound of formula (I)
- wherein
- X1 is a carbon or a nitrogen atom;
- p is zero or an integer from 1 to 3;
- each R, when present, is H or halogen;
- R1 is —H, —CN or (C1-C6) alkyl;
- B is (C3-C8)heterocycloalkyl,
- or
- B is a group of formula R2R3N—(C1-C6) alkyl, optionally substituted by one or more substituents selected from hydroxyl, (C1-C6) alkyl, (C1-C6) hydroxyalkyl, (C1-C6) alkoxycarbonyl, (C3-C10) cycloalkoxycarbonyl, aryl (C1-C6) alkoxycarbonyl;
- wherein
- R2 and R3, the same or different, are selected from the group consisting of
- —H,
- (C1-C6) alkyl,
- (C1-C6) hydroxyalkyl,
- (C3-C8)heterocycloalkyl, further optionally substituted by one or more (C1-C6) alkyl;
- or
- B is a group of formula R2R3N—(C1-C6) alkyl, optionally substituted by one or more substituents selected from hydroxyl, (C1-C6) alkyl, (C1-C6) hydroxyalkyl, (C1-C6) alkoxycarbonyl, (C3-C10) cycloalkoxycarbonyl, aryl (C1-C6) alkoxycarbonyl;
- wherein
- R2 and R3, taken together with the nitrogen atom they are linked to, form a heterocyclic ring, preferably a 4 to 6 membered mono-cyclic saturated heterocyclic ring, wherein at least one further ring carbon atom is optionally replaced by at least one further group independently selected from N, NH, S or O and/or may bear an -oxo (═O) substituent group, said heterocyclic ring is further optionally including spiro disubstitution;
- and said heterocyclic ring in its turn is further optionally substituted by one or more substituents selected from hydroxyl, (C1-C6) alkyl, (C1-C6) hydroxyalkyl, (C1-C6) alkoxycarbonyl, (C3-C10) cycloalkoxycarbonyl, Aryl (C1-C6) alkoxycarbonyl;
- or
- B is a group of formula R2R3N—(C1-C6) alkyl, optionally substituted by one or more substituents selected from hydroxyl, (C1-C6) alkyl, (C1-C6) hydroxyalkyl, (C1-C6) alkoxycarbonyl, (C3-C10) cycloalkoxycarbonyl, aryl (C1-C6) alkoxycarbonyl;
- wherein
- R3 is selected from the group consisting of
- —H,
- (C1-C6) alkyl,
- (C1-C6) hydroxyalkyl,
- (C3-C8) heterocycloalkyl, further optionally substituted by one or more (C1-C6) alkyl;
- R2 is a divalent group —(CH2)q—, wherein q is an integer from 1 to 3;
- said divalent group being connected to the carbon atom in ortho position on the adjacent phenyl ring to form a heterocyclic ring, preferably a 4 to 10 membered heterocyclic ring fused with the phenyl ring;
- said heterocyclic ring being optionally in its turn further substituted with one or more group selected from (C1-C6) alkyl, (C1-C6) hydroxyalkyl;
- or
- B is a divalent group —(CH2)s—, wherein s is an integer from 2 to 8, said divalent group being connected to the adjacent carbon in ortho position on the phenyl ring to form a fused ring;
- preferably a 4 to 10 membered monocyclic ring fused with the phenyl ring;
- said ring being further substituted with one or more —NH2;
- and pharmaceutically acceptable salts and solvates thereof.
(canceled)
Dependencies are inferred from the claim text.